Shilpa Medicare Launches Hybrid CDMO Model for Small and Large Molecules

• Shilpa Medicare has launched a hybrid CDMO model serving both small and large molecule customers, with a focus on oncology.

• The company offers a dual approach, providing contract manufacturing services as well as fully developed products for exclusive B2B licensing.

Shilpa Medicare has introduced a new hybrid CDMO model that caters to both small and large molecule pharmaceutical companies, including peptide-based therapeutics. The model is designed to provide flexible outsourcing solutions, with oncology as a core area of expertise.

In addition to traditional CDMO services, Shilpa offers off-the-shelf novel formulations for exclusive business-to-business (B2B) licensing. This dual approach enables pharmaceutical companies to expedite market entry by licensing fully developed products while also benefiting from Shilpa’s contract manufacturing capabilities. Currently, the company has multiple assets in its pipeline and three late-stage products available for licensing.

“Our goal is to offer pharmaceutical and biotech customers multiple flexible pathways to bring commercial products to market,” said Vishnukant C. Bhutada, Managing Director of Shilpa Medicare. “On the one hand, they can leverage our development teams, cutting-edge technologies, and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high demand at DCAT. On the other, we have a pipeline of fully developed products that are available for exclusive licensing, eliminating development risks for our partners. However, we remain strictly a B2B-only company, ensuring we never compete with our clients.”

Shilpa’s CDMO formulation services cover a broad range of delivery formats, including oral solids, topicals, injectables, transdermal patches, ophthalmic delivery, and oral thin films. Its manufacturing sites hold approvals from global regulatory agencies such as the FDA, EMA, PMDA, TGA, and MHRA.